Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of respiratory diseases
3.2.1.2 Rising burden of diseases such as influenza, pneumonia, pertussis, and respiratory syncytial virus (RSV)
3.2.1.3 Rising technological advancements
3.2.1.4 Growing healthcare expenditure
3.2.2 Industry pitfalls & challenges
3.2.2.1 Complexity of developing vaccines due to evolving pathogens, increased expenses, and extended development times
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Porter's analysis
3.7 PESTEL analysis
3.8 Future market trends
3.9 Gap analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Technology, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Viral vector
5.3 mRNA
5.4 Conjugate
5.5 Live attenuated
5.6 Inactivated
5.7 Recombinant
5.8 Other technologies
Chapter 6 Market Estimates and Forecast, By Age Group, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Pediatric
6.3 Adult
Chapter 7 Market Estimates and Forecast, By Infection, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 COVID-19
7.3 Influenza
7.4 Respiratory syncytial virus (RSV)
7.5 Pneumonia
7.6 Other infections
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Other distribution channels
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Italy
9.3.5 Spain
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 Middle East and Africa
9.6.1 Saudi Arabia
9.6.2 South Africa
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 AstraZeneca
10.2 Emergent BioSolutions Inc.
10.3 GSK plc.
10.4 Johnson & Johnson Services, Inc.
10.5 Merck & Co., Inc.
10.6 Novavax
10.7 Pfizer Inc.
10.8 Sanofi SA
10.9 Serum Institute of India Pvt. Ltd.
10.10 SINOVAC
